neurovascular
(4)
Penumbra, Inc.
Penumbra, Inc. is an Alameda, California medical device company that builds tools to pull life-threatening blood clots out of the body. Founded in 2004 by attorney-turned-CEO Adam Elsesser and neuro-interventional surgeon Dr. Arani Bose, it pioneered aspiration-based mechanical thrombectomy for acute ischemic stroke and expanded into peripheral, venous, and pulmonary clot removal with its Indigo and Lightning Flash systems. The company also runs an Immersive Healthcare arm using virtual reality (the REAL System) for rehabilitation and wellness. Public on the NYSE since 2015 under ticker PEN, Penumbra posted $1.4 billion in 2025 revenue and agreed in January 2026 to be acquired by Boston Scientific in a roughly $14.5 billion deal.
Nventric, Inc.
Nventric, Inc. is a medical device company and contract development and manufacturing organization (CDMO) headquartered in Arcadia, California, with operations in Seoul, South Korea. Founded in 2019 by engineers with backgrounds at Abbott Vascular and Johnson & Johnson, Nventric designs and builds minimally invasive vascular devices - covering neurovascular, coronary, and electrophysiology applications - from concept through scalable, ISO 13485-certified manufacturing. Its own-branded neurovascular line, including the ULTRIVA stent retriever and EVOGLIDE distal access catheter, targets acute ischemic stroke, while its OEM/CDMO services help device companies move products from prototype to commercialization.
RapidAI
RapidAI builds FDA-cleared clinical AI software that reads CT, CTA, CT perfusion and MRI scans to flag stroke, aneurysms and pulmonary embolisms in minutes - giving hospital teams a faster path to treatment. The platform began life as the Stanford spin-out iSchemaView and now runs in more than 2,000 hospitals across 100+ countries.
Viz.ai
Viz.ai is an AI-powered care coordination platform trusted by over 2,000 hospitals across the United States. The company's suite of 50+ FDA-cleared algorithms analyzes medical imaging data in real time - detecting strokes, brain hemorrhages, aneurysms, pulmonary embolisms, and cardiac conditions - then instantly alerts the right clinical team so treatment can begin minutes faster. Founded in 2016 by neurosurgeon Dr. Chris Mansi and machine learning researcher Dr. David Golan, Viz.ai has grown into a platform covering 230 million lives, supporting 70,000+ healthcare providers, and partnering with 14+ leading pharmaceutical companies to accelerate drug development and patient access.